Literature DB >> 29650525

Flushing Disorders Associated with Gastrointestinal Symptoms: Part 1, Neuroendocrine Tumors, Mast Cell Disorders and Hyperbasophila.

Vaibhav Rastogi1,2, Devina Singh3, Joseph J Mazza4, Dipendra Parajuli5, Steven H Yale6,2.   

Abstract

Flushing is the subjective sensation of warmth accompanied by visible cutaneous erythema occurring throughout the body with a predilection for the face, neck, pinnae, and upper trunk where the skin is thinnest and cutaneous vessels are superficially located and in greatest numbers. Flushing can be present in either a wet or dry form depending upon whether neural-mediated mechanisms are involved. Activation of the sympathetic nervous system results in wet flushing, accompanied by diaphoresis, due to concomitant stimulation of eccrine sweat glands. Wet flushing is caused by certain medications, panic disorder and paroxysmal extreme pain disorder (PEPD). Vasodilator mediated flushing due to the formation and release of a variety of biogenic amines, neuropeptides and phospholipid mediators such as histamine, serotonin and prostaglandins, respectively, typically presents as dry flushing where sweating is characteristically absent. Flushing occurring with neuroendocrine tumors accompanied by gastrointestinal symptoms is generally of the dry flushing variant, which may be an important clinical clue to the differential diagnosis. A number of primary diseases of the gastrointestinal tract cause flushing, and conversely extra-intestinal conditions are associated with flushing and gastrointestinal symptoms. Gastrointestinal findings vary and include one or more of the following non-specific symptoms such as abdominal pain, nausea, vomiting, diarrhea or constipation. The purpose of this review is to provide a focused comprehensive discussion on the presentation, pathophysiology, diagnostic evaluation and management of those diseases that arise from the gastrointestinal tract or other site that may cause gastrointestinal symptoms secondarily accompanied by flushing. This review is divided into two parts given the scope of conditions that cause flushing and affect the gastrointestinal tract: Part 1 covers neuroendocrine tumors (carcinoid, pheochromocytomas, vasoactive intestinal polypeptide, medullary carcinoma of the thyroid), polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS), and conditions involving mast cells and basophils; while Part 2 covers dumping syndrome, mesenteric traction syndrome, rosacea, hyperthyroidism and thyroid storm, anaphylaxis, panic disorders, paroxysmal extreme pain disorder, and food, alcohol and medications.
© 2018 Marshfield Clinic.

Entities:  

Keywords:  Flushing; Gastrointestinal; Neuroendocrine Tumor; Systemic Mastocytosis; human

Mesh:

Year:  2018        PMID: 29650525      PMCID: PMC6108509          DOI: 10.3121/cmr.2017.1379a

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  76 in total

Review 1.  AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids.

Authors:  Eric H Liu; Carmen C Solorzano; Laurence Katznelson; Aaron I Vinik; Richard Wong; Gregory Randolph
Journal:  Endocr Pract       Date:  2015-05       Impact factor: 3.443

Review 2.  Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours.

Authors:  P Tomassetti; M Migliori; S Lalli; D Campana; V Tomassetti; R Corinaldesi
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

3.  The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum.

Authors:  Lowell B Anthony; Jonathan R Strosberg; David S Klimstra; William J Maples; Thomas M O'Dorisio; Richard R P Warner; Gregory A Wiseman; Al B Benson; Rodney F Pommier
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

Review 4.  Carcinoid tumors and fibrosis: an association with no explanation.

Authors:  Irvin M Modlin; Michael D Shapiro; Mark Kidd
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

Review 5.  Fibrosis and carcinoid syndrome: from causation to future therapy.

Authors:  Maralyn Druce; Andrea Rockall; Ashley B Grossman
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

Review 6.  Ileal carcinoid tumors and intestinal ischemia.

Authors:  L Strobbe; E D'Hondt; C Ramboer; H Ceuppens; P Hinnekens; M Verhamme
Journal:  Hepatogastroenterology       Date:  1994-10

7.  Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1.

Authors:  Mark Kidd; Irvin M Modlin; Roswitha Pfragner; Geeta N Eick; Manish C Champaneria; Anthony K Chan; Robert L Camp; Shrikant M Mane
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

Review 8.  Thyroid disorders and gastrointestinal and liver dysfunction: A state of the art review.

Authors:  Angelos Kyriacou; John McLaughlin; Akheel A Syed
Journal:  Eur J Intern Med       Date:  2015-08-08       Impact factor: 4.487

Review 9.  Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.

Authors:  Günter Klöppel; Guido Rindi; Martin Anlauf; Aurel Perren; Paul Komminoth
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

10.  Characterization of a pancreatic tumor containing vasoactive intestinal peptide, neurotensin, and pancreatic polypeptide.

Authors:  A Shulkes; R Boden; I Cook; N Gallagher; J B Furness
Journal:  J Clin Endocrinol Metab       Date:  1984-01       Impact factor: 5.958

View more
  6 in total

Review 1.  Sex differences in carcinoid syndrome: A gap to be closed.

Authors:  Rosaria M Ruggeri; Barbara Altieri; Erika Grossrubatcher; Roberto Minotta; Maria Grazia Tarsitano; Virginia Zamponi; Andrea MIsidori; Antongiulio Faggiano; Anna Maria Colao
Journal:  Rev Endocr Metab Disord       Date:  2022-03-16       Impact factor: 6.514

2.  Chronic venulectasias secondary to persistent flushing in the setting of a metastatic well-differentiated neuroendocrine tumor.

Authors:  Eleanor M Pope; Kathryn E Somers
Journal:  JAAD Case Rep       Date:  2022-06-22

Review 3.  Vasoactive intestinal peptide secreting tumour: An overview.

Authors:  Esther Una Cidon
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

Review 4.  Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.

Authors:  Francesca Spada; Roberta E Rossi; Elda Kara; Alice Laffi; Sara Massironi; Manila Rubino; Franco Grimaldi; Sherrie Bhoori; Nicola Fazio
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-04

5.  European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease.

Authors:  Simona Grozinsky-Glasberg; Joseph Davar; Johannes Hofland; Rebecca Dobson; Vikas Prasad; Andreas Pascher; Timm Denecke; Margot E T Tesselaar; Francesco Panzuto; Anders Albåge; Heidi M Connolly; Jean-Francois Obadia; Rachel Riechelmann; Christos Toumpanakis
Journal:  J Neuroendocrinol       Date:  2022-05-25       Impact factor: 3.870

6.  Aldh2 Attenuates Stem Cell Factor/Kit-Dependent Signaling and Activation in Mast Cells.

Authors:  Do-Kyun Kim; Young-Eun Cho; Byoung-Joon Song; Toshihiro Kawamoto; Dean D Metcalfe; Ana Olivera
Journal:  Int J Mol Sci       Date:  2019-12-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.